BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Study or Subgroup	Sacubitril/valsartan Events	Sacubitril/valsartan Total	Control Events	Control Total	Weight	Risk Ratio M-H, Fixed, 95% CI
AWAKE-HF 2019	6	70	4	70	0.2%	1.50 [0.44, 5.09]
CLCZ696B2223	0	8	0	8		Not estimable
EVALUTE-HF 2019	2	232	1	233	0.0%	2.01 [0.18, 22.00]
Li J 2019 (1)	3	62	5	64	0.2%	0.62 [0.15, 2.48]
OUTSTEP-HF	20	310	28	311	1.2%	0.72 [0.41, 1.24]
PARADIGM-HF 2014	1943	4209	2142	4233	94.6%	0.91 [0.87, 0.95]
PIONEER-HF 2018	44	443	74	444	3.3%	0.60 [0.42, 0.84]
PRIME-HF 2019	7	60	9	58	0.4%	0.75 [0.30, 1.89]
Total (95% CI)		**5394**		**5421**	**100.0%**	**0.90 [0.86, 0.94]**
Total events	2025		2263			

Heterogeneity: Chi² = 7.91, df = 6 (P = 0.24); I² = 24%
Test for overall effect: Z = 4.72 (P < 0.00001)